Literature DB >> 29956209

The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease.

Wei Jia1,2, Cynthia Rajani3.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is defined as the presence of excess fat in the liver parenchyma in the absence of excess alcohol consumption and overt inflammation. It has also been described as the hepatic manifestation of metabolic syndrome (Than NN, Newsome PN, Atherosclerosis. 239:192-202, 2015). The incidence of NAFLD has been reported to be 43-60% in diabetics, ~90% in patients with hyperlipidemia and 91% in morbidly obese patients (Than NN, Newsome PN, Atherosclerosis. 239:192-202, 2015, Machado M, Marques-Vidal P, Cortez-Pinto H, J Hepatol, 45:600-606, 2006, Vernon G, Baranova A, Younossi ZM, Aliment Pharmacol Ther, 34:274-285, 2011). The risk factors that have been associated with the development of NAFLD include male gender, increasing age, obesity, insulin resistance, diabetes and hyperlipidemia (Attar BM, Van Thiel DH, Sci World J, 2013:481893, 2013, Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A, Forum Nutr, 5:1544-1460, 2013). All of these risk factors have been linked to alterations of the gut microbiota, ie., gut dysbiosis (He X, Ji G, Jia W, Li H, Int J Mol Sci, 17:300, 2016). However, it must be pointed out that the prevalence of NAFLD in normal weight individuals without metabolic risk factors is ~16% (Than NN, Newsome PN, Atherosclerosis. 239:192-202, 2015). This fact has led some investigators to hypothesize that the gut microbiota can impact lipid metabolism in the liver independently of obesity-related metabolic factors (Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold g, et al., Gut, 65:330 339, 2016) (Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, et al., Gut, 62:1787-1794, 2013). In this chapter, we will explore the effect of the gut microbiota on hepatic lipid metabolism and how this affects the development of NAFLD.

Entities:  

Keywords:  Bile acids; Diabetes; Gut microbiota; Metabolic syndrome; Non-alcoholic fatty liver disease; Steatosis

Mesh:

Year:  2018        PMID: 29956209     DOI: 10.1007/978-981-10-8684-7_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

Review 1.  Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis.

Authors:  Mehmet Sayiner; Brian Lam; Pegah Golabi; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2018-11-15       Impact factor: 4.409

2.  Isolation and Characterization of Potentially Probiotic Bacterial Strains from Mice: Proof of Concept for Personalized Probiotics.

Authors:  Larissa S Celiberto; Roseli Aparecida Pinto; Elizeu Antonio Rossi; Bruce A Vallance; Daniela C U Cavallini
Journal:  Nutrients       Date:  2018-11-05       Impact factor: 5.717

Review 3.  Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates.

Authors:  Ashiq Khan; Zitong Ding; Muhammad Ishaq; Ali Sher Bacha; Israr Khan; Anum Hanif; Wenyuan Li; Xusheng Guo
Journal:  Int J Biol Sci       Date:  2021-02-08       Impact factor: 6.580

Review 4.  Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases.

Authors:  Ji-Won Park; Sung-Eun Kim; Na Young Lee; Jung-Hee Kim; Jang-Han Jung; Myoung-Kuk Jang; Sang-Hoon Park; Myung-Seok Lee; Dong-Joon Kim; Hyoung-Su Kim; Ki Tae Suk
Journal:  Int J Mol Sci       Date:  2021-12-31       Impact factor: 5.923

5.  Alterations in the oral microbiome of individuals with a healthy oral environment following COVID-19 vaccination.

Authors:  Osamu Uehara; Yoshihiro Abiko; Toshiyuki Nagasawa; Tetsuro Morikawa; Daichi Hiraki; Fumiya Harada; Yutaka Kawano; Seiko Toraya; Hirofumi Matsuoka; Durga Paudel; Shintaro Shimizu; Koki Yoshida; Masahiro Asaka; Yasushi Furuichi; Hiroko Miura
Journal:  BMC Oral Health       Date:  2022-03-03       Impact factor: 2.757

Review 6.  Gut microbiota is a potential goalkeeper of dyslipidemia.

Authors:  Lirong Lei; Ning Zhao; Lei Zhang; Jiamei Chen; Xiaomin Liu; Shenghua Piao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-13       Impact factor: 6.055

Review 7.  The Interaction among Microbiota, Epigenetic Regulation, and Air Pollutants in Disease Prevention.

Authors:  Alessandra Pulliero; Deborah Traversi; Elena Franchitti; Martina Barchitta; Alberto Izzotti; Antonella Agodi
Journal:  J Pers Med       Date:  2021-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.